LTSL
Effective, elegant, patented
These new liposomes are composed of lipid molecules that quickly change structure when heated to a specific temperature, creating channels in the liposome bilayer that allow encapsulated drug to rapidly disperse into the surrounding tissue. As a result, LTSL enables delivery of higher concentrations of proven chemotherapy drugs directly to the tumor, stopping the progression of cancer and minimizing systemic toxicity.
 Leaky tumor vessels 37ºC |
 Heat adds permeability 39 < T < 42°C |
 Mechanical release at 39º-42º C |
The science of LTSL has already been reviewed and validated by major scientific institutions and investigators. The technology, further developed by Celsion, is being used to enhance existing chemotherapeutics.
The illustration below summarizes the results of a pre-clinical tumor delay model in mice. Human tumors which were allowed to grow up to five times their original volume were implanted in the legs of individual mice. The mice were then separated into four groups and treated with doxorubicin (Chart A), a non-temperature sensitive liposomal formulation of doxorubicin (Chart B), a temperature sensitive liposomal formulation of doxorubicin with a higher release target temperature of around 43ºC (Chart C) and ThermoDox® (Chart D) which releases doxorubicin at a target temperature of 39-42ºC. The tumor containing leg was immersed in a water bath at 42ºC. The mice were followed for 60 days. In groups A, B and C, although the tumor growth was initially slowed, every tumor grew to five time its volume in 60 days. In the ThermoDox treated animals, on average the tumor regressed within ten days and did not re-grow during the 60 day follow-up period.
 |
 |
|
|